Luoxin Pharmaceuticals Group Stock Co Ltd

SHE:002793 China Drug Manufacturers - Specialty & Generic
Market Cap
$712.98 Million
CN¥5.23 Billion CNY
Market Cap Rank
#11269 Global
#2622 in China
Share Price
CN¥4.81
Change (1 day)
-0.62%
52-Week Range
CN¥3.57 - CN¥6.50
All Time High
CN¥25.07
About

Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. … Read more

Luoxin Pharmaceuticals Group Stock Co Ltd (002793) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: 0.059x

Based on the latest financial reports, Luoxin Pharmaceuticals Group Stock Co Ltd (002793) has a cash flow conversion efficiency ratio of 0.059x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥90.75 Million) by net assets (CN¥1.53 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Luoxin Pharmaceuticals Group Stock Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how Luoxin Pharmaceuticals Group Stock Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Luoxin Pharmaceuticals Group Stock Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Luoxin Pharmaceuticals Group Stock Co Ltd ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Luoxin Pharmaceuticals Group Stock Co Ltd (2011–2024)

The table below shows the annual cash flow conversion efficiency of Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥1.46 Billion CN¥-157.85 Million -0.108x -150.33%
2023-12-31 CN¥2.57 Billion CN¥552.79 Million 0.215x +175.66%
2022-12-31 CN¥3.31 Billion CN¥-939.13 Million -0.284x -1215.03%
2021-12-31 CN¥4.74 Billion CN¥120.63 Million 0.025x +442.04%
2020-12-31 CN¥4.35 Billion CN¥-32.40 Million -0.007x -125.36%
2019-12-31 CN¥3.96 Billion CN¥116.33 Million 0.029x -76.59%
2018-12-31 CN¥909.89 Million CN¥114.12 Million 0.125x -7.52%
2017-12-31 CN¥754.19 Million CN¥102.27 Million 0.136x +30.19%
2016-12-31 CN¥698.33 Million CN¥72.74 Million 0.104x -39.16%
2015-12-31 CN¥339.50 Million CN¥58.12 Million 0.171x +29.11%
2014-12-31 CN¥315.46 Million CN¥41.83 Million 0.133x -48.50%
2013-12-31 CN¥251.50 Million CN¥64.75 Million 0.257x +58.84%
2012-12-31 CN¥205.54 Million CN¥33.31 Million 0.162x -47.10%
2011-12-31 CN¥151.87 Million CN¥46.53 Million 0.306x --